Distinct cellular immune profiles in lung adenocarcinoma manifesting as pure ground glass opacity versus solid nodules

[1]  O. Elemento,et al.  Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma , 2022, Cell reports.

[2]  E. Batlle,et al.  Overcoming TGFβ-mediated immune evasion in cancer , 2021, Nature Reviews Cancer.

[3]  X. Yi,et al.  Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity. , 2021, American journal of respiratory and critical care medicine.

[4]  Y. Choi,et al.  Early lung carcinogenesis and tumor microenvironment observed by single-cell transcriptome analysis , 2021, Translational oncology.

[5]  Yi-long Wu,et al.  Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy , 2021, Journal for ImmunoTherapy of Cancer.

[6]  F. Bai,et al.  Decoding the multicellular ecosystem of lung adenocarcinoma manifested as pulmonary subsolid nodules by single-cell RNA sequencing , 2021, Science Advances.

[7]  Lequn Li,et al.  Tumor-infiltrating CD8+ T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells. , 2020, Lung cancer.

[8]  Xiaodong Yang,et al.  Single-cell transcriptome atlas of lung adenocarcinoma featured with ground glass nodules , 2020, Cell discovery.

[9]  P. A. Futreal,et al.  Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features , 2020, Nature Communications.

[10]  Jue Fan,et al.  Synchronous ground‐glass nodules showed limited response to anti‐PD‐1/PD‐L1 therapy in patients with advanced lung adenocarcinoma , 2020, Clinical and Translational Medicine.

[11]  Chi Zhang,et al.  Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer , 2020, Genome Biology.

[12]  Kenji Suzuki,et al.  Prognostic classification of multiple primary lung cancers based on a ground glass opacity component. , 2020, The Annals of thoracic surgery.

[13]  Yang Zhang,et al.  Imaging Features Suggestive of Multiple Primary Lung Adenocarcinomas , 2019, Annals of Surgical Oncology.

[14]  A. Borczuk,et al.  Genomic Underpinnings of Tumor Behavior in in situ and Early Lung Adenocarcinoma. , 2019, American journal of respiratory and critical care medicine.

[15]  Joshua D. Campbell,et al.  Genomic and immune profiling of pre-invasive lung adenocarcinoma , 2019, Nature Communications.

[16]  J. Roth,et al.  OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study , 2019, Journal of Thoracic Oncology.

[17]  J. Soh,et al.  Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas , 2019, Biomolecules.

[18]  Yi-long Wu,et al.  Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early-Invasive Lung Adenocarcinoma. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Yang Zhang,et al.  Distinct prognostic factors in patients with stage I non-small cell lung cancer with radiologic part solid or solid lesions. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  K. Ashizawa,et al.  Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma , 2019, Nature Communications.

[21]  M. Tsuboi,et al.  Ground-Glass Opacity Is a Strong Prognosticator for Pathologic Stage IA Lung Adenocarcinoma. , 2019, The Annals of thoracic surgery.

[22]  L. Tran,et al.  The immune contexture associates with the genomic landscape in lung adenomatous premalignancy. , 2019, Cancer research.

[23]  N. Navani,et al.  Immunotherapy in Non-Small Cell Lung Cancer. Which Patients and at Which Stage? , 2019, American journal of respiratory and critical care medicine.

[24]  Weijun Peng,et al.  Lung Adenocarcinomas Manifesting as Radiological Part‐Solid Nodules Define a Special Clinical Subtype , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  Takuo Hayashi,et al.  Distinct Clinicopathologic Characteristics and Prognosis Based on the Presence of Ground Glass Opacity Component in Clinical Stage IA Lung Adenocarcinoma , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Boxi Kang,et al.  Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing , 2018, Nature Medicine.

[27]  M. Kris,et al.  Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3). , 2018 .

[28]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[29]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[30]  P. A. Futreal,et al.  Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. , 2017, Cancer research.

[31]  E. King,et al.  Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer , 2017, Nature Immunology.

[32]  Yi Zhang,et al.  Tumor-associated macrophages: from basic research to clinical application , 2017, Journal of Hematology & Oncology.

[33]  A. Bankier,et al.  Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. , 2017, Radiology.

[34]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[35]  M. Tsuboi,et al.  Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung. , 2016, Lung cancer.

[36]  G. Altavilla,et al.  Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. , 2015, Translational lung cancer research.

[37]  J. Madore,et al.  PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. , 2015, Lung cancer.

[38]  S. Lam,et al.  Probability of cancer in pulmonary nodules detected on first screening CT. , 2013, The New England journal of medicine.

[39]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[40]  Charles A Powell,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. , 2011, Proceedings of the American Thoracic Society.

[41]  S. Quezada,et al.  Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication , 2011, Immunological reviews.

[42]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[44]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[45]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[46]  Wei Liu,et al.  Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer , 2018, Cellular & Molecular Immunology.

[47]  Hiromasa Yamamoto,et al.  Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. , 2012, Lung cancer.

[48]  Liu Yan-hui,et al.  Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[49]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[50]  J. Cooper.  Ajcc Cancer Staging Manual , 1997 .